[
  {
    "id": "91c27d10-9068-4a9a-9946-4bf98dc71bc9",
    "biomarkerName": "HER2",
    "testingMethod": "IHC and/or FISH",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Treatment selection"
    ],
    "nccnReference": "BINV-2",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "low": "IHC 1-2+/FISH negative",
      "negative": "IHC 0-1+ or FISH negative",
      "positive": "IHC 3+ or FISH amplified"
    },
    "therapeuticImplications": [
      "Anti-HER2 therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:29.010Z",
    "updatedAt": "2025-06-28T17:06:29.010Z"
  },
  {
    "id": "1cd71259-87da-4cb7-a20c-0005e3addc93",
    "biomarkerName": "ER/PR",
    "testingMethod": "Immunohistochemistry",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Endocrine therapy selection"
    ],
    "nccnReference": "BINV-2",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "negative": "<1% nuclear staining",
      "positive": "≥1% nuclear staining"
    },
    "therapeuticImplications": [
      "Endocrine therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:29.088Z",
    "updatedAt": "2025-06-28T17:06:29.088Z"
  },
  {
    "id": "70ed615e-94f5-488a-9df6-a8d1916f5286",
    "biomarkerName": "HER2",
    "testingMethod": "IHC and/or FISH",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Treatment selection"
    ],
    "nccnReference": "BINV-5",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "low": "IHC 1-2+/FISH negative",
      "negative": "IHC 0-1+ or FISH negative",
      "positive": "IHC 3+ or FISH amplified"
    },
    "therapeuticImplications": [
      "Anti-HER2 therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:29.611Z",
    "updatedAt": "2025-06-28T17:06:29.611Z"
  },
  {
    "id": "79c04b40-4bde-4a26-bc21-a29987b71873",
    "biomarkerName": "ER/PR",
    "testingMethod": "Immunohistochemistry",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Endocrine therapy selection"
    ],
    "nccnReference": "BINV-5",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "negative": "<1% nuclear staining",
      "positive": "≥1% nuclear staining"
    },
    "therapeuticImplications": [
      "Endocrine therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:29.697Z",
    "updatedAt": "2025-06-28T17:06:29.697Z"
  },
  {
    "id": "03fbcf61-c10b-4640-8510-2edfac55c8e2",
    "biomarkerName": "ER/PR",
    "testingMethod": "Immunohistochemistry",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Endocrine therapy selection"
    ],
    "nccnReference": "BINV-18",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "negative": "<1% nuclear staining",
      "positive": "≥1% nuclear staining"
    },
    "therapeuticImplications": [
      "Endocrine therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:31.712Z",
    "updatedAt": "2025-06-28T17:06:31.712Z"
  },
  {
    "id": "56f28769-4694-40f4-92be-ef027cd9e4f1",
    "biomarkerName": "HER2",
    "testingMethod": "IHC and/or FISH",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Treatment selection"
    ],
    "nccnReference": "BINV-25",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "low": "IHC 1-2+/FISH negative",
      "negative": "IHC 0-1+ or FISH negative",
      "positive": "IHC 3+ or FISH amplified"
    },
    "therapeuticImplications": [
      "Anti-HER2 therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:32.376Z",
    "updatedAt": "2025-06-28T17:06:32.376Z"
  },
  {
    "id": "0748481b-16eb-4674-9efd-bc00d3d94be2",
    "biomarkerName": "ER/PR",
    "testingMethod": "Immunohistochemistry",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Endocrine therapy selection"
    ],
    "nccnReference": "BINV-25",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "negative": "<1% nuclear staining",
      "positive": "≥1% nuclear staining"
    },
    "therapeuticImplications": [
      "Endocrine therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:32.450Z",
    "updatedAt": "2025-06-28T17:06:32.450Z"
  },
  {
    "id": "89636e10-dfda-425e-9a1f-2f3513285c0f",
    "biomarkerName": "HER2",
    "testingMethod": "IHC and/or FISH",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Treatment selection"
    ],
    "nccnReference": "BINV-26",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "low": "IHC 1-2+/FISH negative",
      "negative": "IHC 0-1+ or FISH negative",
      "positive": "IHC 3+ or FISH amplified"
    },
    "therapeuticImplications": [
      "Anti-HER2 therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:32.743Z",
    "updatedAt": "2025-06-28T17:06:32.743Z"
  },
  {
    "id": "77531671-e251-4583-a3f4-5e59b534b06e",
    "biomarkerName": "ER/PR",
    "testingMethod": "Immunohistochemistry",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Endocrine therapy selection"
    ],
    "nccnReference": "BINV-26",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "negative": "<1% nuclear staining",
      "positive": "≥1% nuclear staining"
    },
    "therapeuticImplications": [
      "Endocrine therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:32.817Z",
    "updatedAt": "2025-06-28T17:06:32.817Z"
  },
  {
    "id": "ff32d93a-4d46-48b4-b266-c199d9b6928a",
    "biomarkerName": "HER2",
    "testingMethod": "IHC and/or FISH",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Treatment selection"
    ],
    "nccnReference": "BINV-28",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "low": "IHC 1-2+/FISH negative",
      "negative": "IHC 0-1+ or FISH negative",
      "positive": "IHC 3+ or FISH amplified"
    },
    "therapeuticImplications": [
      "Anti-HER2 therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:33.112Z",
    "updatedAt": "2025-06-28T17:06:33.112Z"
  },
  {
    "id": "a98500af-8933-4f5d-8ba9-a3c598ad6a49",
    "biomarkerName": "ER/PR",
    "testingMethod": "Immunohistochemistry",
    "cancerType": "breast",
    "clinicalIndications": [
      "All invasive breast cancers",
      "Endocrine therapy selection"
    ],
    "nccnReference": "BINV-28",
    "evidenceLevel": "Category 1",
    "testingTiming": "At diagnosis",
    "interpretationCriteria": {
      "negative": "<1% nuclear staining",
      "positive": "≥1% nuclear staining"
    },
    "therapeuticImplications": [
      "Endocrine therapy selection",
      "Prognosis"
    ],
    "qualityRequirements": [
      "CAP/ASCO guidelines"
    ],
    "reportingStandards": [
      "Standardized reporting required"
    ],
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-28T17:06:33.186Z",
    "updatedAt": "2025-06-28T17:06:33.186Z"
  },
  {
    "id": "77f0ae30-25a1-41fe-889a-3ce40e6fa053",
    "biomarkerName": "HER2",
    "testingMethod": "IHC/FISH",
    "cancerType": "Ampullary Adenocarcinoma",
    "clinicalIndications": [
      "Advanced ampullary adenocarcinoma",
      "Metastatic disease",
      "Treatment selection"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 1",
    "testingTiming": null,
    "interpretationCriteria": "HER2 overexpression positive: IHC 3+ or FISH amplified",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:17:04.939Z",
    "updatedAt": "2025-06-29T00:17:04.939Z"
  },
  {
    "id": "e8534e55-0607-4ce2-bb9a-9781c592e1d7",
    "biomarkerName": "PD-L1",
    "testingMethod": "IHC (CPS scoring)",
    "cancerType": "Ampullary Adenocarcinoma",
    "clinicalIndications": [
      "Advanced disease",
      "Immunotherapy selection",
      "First-line treatment planning"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 1",
    "testingTiming": null,
    "interpretationCriteria": "CPS ≥1 for pembrolizumab eligibility, CPS ≥5 for optimal benefit",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:17:05.020Z",
    "updatedAt": "2025-06-29T00:17:05.020Z"
  },
  {
    "id": "86ee8e9f-6bbf-4794-816f-63292a78560c",
    "biomarkerName": "MSI-H/dMMR",
    "testingMethod": "IHC for MMR proteins or PCR/NGS for MSI",
    "cancerType": "Ampullary Adenocarcinoma",
    "clinicalIndications": [
      "Treatment planning",
      "Immunotherapy eligibility",
      "Perioperative therapy selection"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 1",
    "testingTiming": null,
    "interpretationCriteria": "MSI-H or dMMR indicates deficient DNA repair",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:17:05.097Z",
    "updatedAt": "2025-06-29T00:17:05.097Z"
  },
  {
    "id": "7f36abcb-ead4-49a2-8491-38e7294252c3",
    "biomarkerName": "CLDN18.2",
    "testingMethod": "IHC",
    "cancerType": "Ampullary Adenocarcinoma",
    "clinicalIndications": [
      "Advanced disease",
      "Targeted therapy selection",
      "First-line treatment"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 1",
    "testingTiming": null,
    "interpretationCriteria": "CLDN18.2 positive by IHC",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:17:05.174Z",
    "updatedAt": "2025-06-29T00:17:05.174Z"
  },
  {
    "id": "f675cd43-16fe-48ad-b971-40462b40c3ba",
    "biomarkerName": "Hereditary Cancer Panel",
    "testingMethod": "Germline genetic testing",
    "cancerType": "Ampullary Adenocarcinoma",
    "clinicalIndications": [
      "All confirmed ampullary adenocarcinoma patients",
      "Positive family history",
      "Risk assessment"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 1",
    "testingTiming": null,
    "interpretationCriteria": "Test for ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:17:05.251Z",
    "updatedAt": "2025-06-29T00:17:05.251Z"
  },
  {
    "id": "267b045e-f6fb-47ef-ad29-16db5312b21a",
    "biomarkerName": "Alkaline Phosphatase",
    "testingMethod": "Serum chemistry",
    "cancerType": "Osteosarcoma",
    "clinicalIndications": [
      "Baseline assessment",
      "Response monitoring",
      "Surveillance"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 2A",
    "testingTiming": null,
    "interpretationCriteria": "Elevated levels may indicate disease activity or progression",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:26:38.806Z",
    "updatedAt": "2025-06-29T00:26:38.806Z"
  },
  {
    "id": "54e546bd-f150-40c8-8011-2c2c28ff1ed6",
    "biomarkerName": "LDH (Lactate Dehydrogenase)",
    "testingMethod": "Serum chemistry",
    "cancerType": "Osteosarcoma",
    "clinicalIndications": [
      "Baseline assessment",
      "Prognostic evaluation",
      "Response monitoring"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 2A",
    "testingTiming": null,
    "interpretationCriteria": "Elevated LDH associated with worse prognosis",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:26:38.883Z",
    "updatedAt": "2025-06-29T00:26:38.883Z"
  },
  {
    "id": "7f716883-2977-488b-8fa4-4d23aa2c2477",
    "biomarkerName": "EWSR1 Rearrangement",
    "testingMethod": "Cytogenetics, FISH, RT-PCR",
    "cancerType": "Ewing Sarcoma",
    "clinicalIndications": [
      "Diagnostic confirmation",
      "Treatment selection"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 2A",
    "testingTiming": null,
    "interpretationCriteria": "90% have one of four specific translocations (EWSR1-FLI1, EWSR1-ERG)",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:26:38.956Z",
    "updatedAt": "2025-06-29T00:26:38.956Z"
  },
  {
    "id": "75088a69-f0d4-4bf4-94d6-0625e886f828",
    "biomarkerName": "CIC-DUX4 Fusion",
    "testingMethod": "Molecular testing, RT-PCR",
    "cancerType": "Ewing-like Sarcoma",
    "clinicalIndications": [
      "Differential diagnosis",
      "Treatment selection"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 2A",
    "testingTiming": null,
    "interpretationCriteria": "Ewing-like sarcoma that can be treated with Ewing protocols",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:26:39.028Z",
    "updatedAt": "2025-06-29T00:26:39.028Z"
  },
  {
    "id": "08f0642f-381b-4df5-ae1d-c1a341482a01",
    "biomarkerName": "BCOR-CCNB3 Fusion",
    "testingMethod": "Molecular testing, RT-PCR",
    "cancerType": "Ewing-like Sarcoma",
    "clinicalIndications": [
      "Differential diagnosis",
      "Treatment selection"
    ],
    "nccnReference": null,
    "evidenceLevel": "Category 2A",
    "testingTiming": null,
    "interpretationCriteria": "Round cell sarcoma with Ewing-like features",
    "therapeuticImplications": null,
    "qualityRequirements": null,
    "reportingStandards": null,
    "costConsiderations": null,
    "specialConsiderations": null,
    "createdAt": "2025-06-29T00:26:39.101Z",
    "updatedAt": "2025-06-29T00:26:39.101Z"
  }
]